FGF23 and disorders of phosphate homeostasis

Xijie Yu, Kenneth White

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.

Original languageEnglish
Pages (from-to)221-232
Number of pages12
JournalCytokine and Growth Factor Reviews
Volume16
Issue number2 SPEC. ISS.
DOIs
StatePublished - Apr 2005

Fingerprint

Growth Disorders
Homeostasis
Phosphates
Fibroblast Growth Factors
Fibrous Dysplasia of Bone
Familial Hypophosphatemic Rickets
Kidney
Calcinosis
Mutation
fibroblast growth factor 23
Vitamin D
Embryonic Development
Renal Insufficiency
Tumors
Bone
Animals
Proteins
Animal Models
Phenotype
Processing

Keywords

  • ADHR
  • FGF
  • FGF23
  • Fibrous dysplasia
  • Metabolic bone disease
  • Phosphate wasting
  • TIO
  • XLH

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

FGF23 and disorders of phosphate homeostasis. / Yu, Xijie; White, Kenneth.

In: Cytokine and Growth Factor Reviews, Vol. 16, No. 2 SPEC. ISS., 04.2005, p. 221-232.

Research output: Contribution to journalArticle

Yu, Xijie ; White, Kenneth. / FGF23 and disorders of phosphate homeostasis. In: Cytokine and Growth Factor Reviews. 2005 ; Vol. 16, No. 2 SPEC. ISS. pp. 221-232.
@article{818c55d174f14a149fd7507f4be07a9f,
title = "FGF23 and disorders of phosphate homeostasis",
abstract = "It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.",
keywords = "ADHR, FGF, FGF23, Fibrous dysplasia, Metabolic bone disease, Phosphate wasting, TIO, XLH",
author = "Xijie Yu and Kenneth White",
year = "2005",
month = "4",
doi = "10.1016/j.cytogfr.2005.01.002",
language = "English",
volume = "16",
pages = "221--232",
journal = "Cytokine and Growth Factor Reviews",
issn = "1359-6101",
publisher = "Elsevier BV",
number = "2 SPEC. ISS.",

}

TY - JOUR

T1 - FGF23 and disorders of phosphate homeostasis

AU - Yu, Xijie

AU - White, Kenneth

PY - 2005/4

Y1 - 2005/4

N2 - It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.

AB - It is well known that fibroblast growth factor (FGF) family members are associated with embryonic development and are critical for basic metabolic functions. This review will focus upon fibroblast growth factor-23 (FGF23) and its roles in disorders associated with phosphate handling. The discovery that mutations in FGF23 were responsible for the isolated renal phosphate wasting disorder autosomal dominant hypophosphatemic rickets (ADHR) has ascribed novel functions to the FGF family. FGF23 circulates in the bloodstream, and animal models demonstrate that FGF23 controls phosphate and Vitamin D homeostasis through the regulation of specific renal proteins. The ADHR mutations in FGF23 produce a protein species less susceptible to proteolytic processing. X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and fibrous dysplasia of bone (FD) are disorders involving phosphate homeostasis that share phenotypes with ADHR, indicating that FGF23 may be a common denominator for the pathophysiology of these syndromes. Our understanding of FGF23 will help to develop novel therapies for phosphate wasting disorders, as well as for disorders of increased serum phosphate, such as tumoral calcinosis, a rare disorder, and renal failure, a common disorder.

KW - ADHR

KW - FGF

KW - FGF23

KW - Fibrous dysplasia

KW - Metabolic bone disease

KW - Phosphate wasting

KW - TIO

KW - XLH

UR - http://www.scopus.com/inward/record.url?scp=18144378440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144378440&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2005.01.002

DO - 10.1016/j.cytogfr.2005.01.002

M3 - Article

VL - 16

SP - 221

EP - 232

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

SN - 1359-6101

IS - 2 SPEC. ISS.

ER -